Health Sciences, Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 8410501, Israel.
Soroka University Medical Center, P.O.B. 151, Beer-Sheva 84101, Israel.
Clin Nutr. 2018 Aug;37(4):1145-1153. doi: 10.1016/j.clnu.2017.04.007. Epub 2017 May 2.
BACKGROUND & AIMS: Data regarding the role of kidney adiposity, its clinical implications, and its dynamics during weight-loss are sparse. We investigated the effect of long-term weight-loss induced intervention diets on dynamics of renal-sinus-fat, an ectopic fat depot, and %renal-parenchymal-fat, lipid accumulation within the renal parenchyma.
We randomized 278 participants with abdominal obesity/dyslipidemia to low-fat or Mediterranean/low-carbohydrate diets, with or without exercise. We quantified renal-sinus-fat and %renal-parenchymal-fat by whole body magnetic-resonance-imaging.
Participants (age = 48 years; 89% men; body-mass-index = 31 kg/m) had 86% retention to the trial after 18 months. Both increased renal-sinus-fat and %renal-parenchymal-fat were directly associated with hypertension, and with higher abdominal deep-subcutaneous-adipose-tissue and visceral-adipose-tissue (p of trend < 0.05 for all) after adjustment for body weight. Higher renal-sinus-fat was associated with lower estimated-glomerular-filtration-rate and with higher microalbuminuria and %HbA1C beyond body weight. After 18 months of intervention, overall renal-sinus-fat (-9%; p < 0.05 vs. baseline) but not %renal-parenchymal-fat (-1.7%; p = 0.13 vs. baseline) significantly decreased, and similarly across the intervention groups. Renal-sinus-fat and %renal-parenchymal-fat changes were correlated with weight-loss per-se (p < 0.05). In a model adjusted for age, sex, and visceral-adipose-tissue changes, 18 months reduction in renal-sinus-fat associated with decreased pancreatic, hepatic and cardiac fats (p < 0.05 for all) and with decreased cholesterol/high-density lipoprotein-cholesterol (HDL-c) (β = 0.13; p = 0.05), triglycerides/HDL-c (β = 0.13; p = 0.05), insulin (β = 0.12; p = 0.05) and gamma glutamyl transpeptidase (β = 0.24; p = 0.001), but not with improved renal function parameters or blood pressure. Decreased intake of sodium was associated with a reduction in %renal-parenchymal-fat, after adjustment for 18 months weight-loss (β = 0.15; p = 0.026) and hypertension (β = 0.14; p = 0.04).
Renal-sinus-fat and renal-parenchymal-fat are fairly related to weight-loss. Decreased renal-sinus-fat is associated with improved hepatic parameters, independent of changes in weight or hepatic fat, rather than with improved renal function or blood pressure parameters. CLINICALTRIALS.
NCT01530724.
关于肾脏脂肪含量的作用、其临床意义及其在减肥过程中的动态变化的数据很少。我们研究了长期减肥诱导的干预饮食对异位脂肪库肾窦脂肪和肾实质脂肪百分比的影响,肾实质脂肪是肾实质内的脂质堆积。
我们将 278 名有腹部肥胖/血脂异常的参与者随机分为低脂或地中海/低碳水化合物饮食,同时进行或不进行运动。我们通过全身磁共振成像定量测量肾窦脂肪和肾实质脂肪百分比。
参与者(年龄 48 岁;89%为男性;体重指数 31kg/m)在 18 个月后有 86%的保留率参与试验。肾窦脂肪和肾实质脂肪百分比的增加与高血压直接相关,与腹部深皮下脂肪组织和内脏脂肪组织的增加呈正相关(所有趋势 p<0.05),调整体重后。较高的肾窦脂肪与估计肾小球滤过率降低以及高于体重的微量白蛋白尿和%HbA1C 相关。经过 18 个月的干预,总体肾窦脂肪(-9%;p<0.05 与基线相比)但不是肾实质脂肪百分比(-1.7%;p=0.13 与基线相比)显著降低,并且在整个干预组中也是如此。肾窦脂肪和肾实质脂肪的变化与体重减轻直接相关(p<0.05)。在调整年龄、性别和内脏脂肪组织变化的模型中,18 个月的肾窦脂肪减少与胰腺、肝脏和心脏脂肪减少相关(所有 p<0.05),与胆固醇/高密度脂蛋白胆固醇(HDL-c)降低相关(β=0.13;p=0.05),与甘油三酯/HDL-c(β=0.13;p=0.05)、胰岛素(β=0.12;p=0.05)和γ谷氨酰转肽酶(β=0.24;p=0.001)相关,但与肾功能参数或血压的改善无关。调整 18 个月的体重减轻(β=0.15;p=0.026)和高血压(β=0.14;p=0.04)后,钠摄入量的减少与肾实质脂肪百分比的降低相关。
肾窦脂肪和肾实质脂肪与体重减轻密切相关。肾窦脂肪减少与肝脏参数改善有关,这与体重或肝脏脂肪的变化无关,而与肾功能或血压参数的改善无关。临床试验。
NCT01530724。